Associated Genetic Biomarkers
EGFR L747P is present in 0.02% of AACR GENIE cases, with lung adenocarcinoma having the greatest prevalence .
EGFR L747P serves as an inclusion eligibility criterion in 3 clinical trials, of which 1 is open and 2 are closed. Of the trials that contain EGFR L747P as an inclusion criterion, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open).
Trials with EGFR L747P in the inclusion eligibility criteria most commonly target non-small cell lung carcinoma, small cell lung carcinoma, squamous cell lung carcinoma, and thymic carcinoma .
Nivolumab, pembrolizumab, ipilimumab, durvalumab, and binimetinib are the most frequent therapies in trials with EGFR L747P as an inclusion criteria .
Significance of EGFR L747P in Diseases
Non-Small Cell Lung Carcinoma +
EGFR is altered in 22.89% of non-small cell lung carcinoma patients with EGFR L747P present in 0.05% of all non-small cell lung carcinoma patients .
EGFR L747P is an inclusion criterion in 2 clinical trials for non-small cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain EGFR L747P and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) .
Malignant Solid Tumor +
EGFR is altered in 7.61% of malignant solid tumor patients with EGFR L747P present in 0.01% of all malignant solid tumor patients .
EGFR L747P is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 0 are open and 1 is closed. Of the trial that contains EGFR L747P and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) .
Colorectal Carcinoma +
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. Liu X, Wu C, Li C, and Boerwinkle E. dbNSFP v3.0: A one-stop database of functional predictions and annotations for human nonsynonymous and splice site SNVs. Human Mutation. 2015;37:235-241.
Liu X, Jian X, and Boerwinkle E. dbNSFP: A lightweight database of human nonsynonymous SNPs and their functional predictions. Human Mutation. 2011;32:894-899.
4. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.